This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           June 17, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store



HPV
 

Researchers discover how ovarian cancer halts body's natural defense against tumor
Weill Cornell Medical College via Medical Xpress
Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report in the June 11 issue of Cell. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


SGO attempts to regain RVUs for Lap Hys and Lymphadenectomy
SGO
SGO is conducting a survey of its gynecologic oncologist Full and Candidate members regarding the number of post-operative visits for laparoscopic hysterectomy (CPT code 58571) and lymphadenectomy (CPT code 38571). An email link to the survey to obtain data needed to calculate accurate Relative Value Units (RVUs) was sent to all gynecologic oncologist Full and Candidate members in the United Statees on June 10, and the deadline for completing the survey is June 24. Please contact Debbie Leopold if you did not receive the survey link.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Highlights from SGO's 2015 Annual Meeting on Women's Cancer
Gynecologic Oncology
The Society of Gynecologic Oncology hosted the 46th Annual Meeting on Women's Cancer at the Hilton Chicago from March 28 to 31, 2015. There were several prevailing themes: (1) surgical innovation; (2) molecular drivers of gynecologic cancers; (3) HPV, cervical cancer, and global health; (4) key clinical trials; and (5) cost-effective care and allocation of health care resources. Within this brief review, we seek to provide a representative snapshot of the four-day meeting featuring 51 plenary presentations, 8 late-breaking abstracts, and the Hugh Barber Lectureship presented by Dr. Tito Fojo from the National Cancer Institute discussing the inherent challenges associated with development and delivery of targeted therapies.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


OVARIAN CANCER


Ovarian cancers sensitive to chemo identified by gene mutations
Medical News Today
Scientists at The University of Texas MD Anderson Cancer Center in Houston have identified a new class of gene mutations that may contribute to outcomes in the treatment of ovarian cancer. Research on the gene family known as ADAMTS could open up a new genetic avenue for the design of ovarian cancer therapies, say the researchers publishing their work in the journal JAMA Oncology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


Scientists find genetic variants key to understanding origins of ovarian cancer
University of Southern California via Medical News Today
New research by an international team including Keck Medicine of USC scientists is bringing the origins of ovarian cancer into sharper focus. The study, published online in the peer-reviewed journal Nature Genetics, highlights the discovery of three genetic variants associated with mucinous ovarian carcinomas, offering the first evidence of genetic susceptibility in this type of ovarian cancer. The research also suggests a link between common pathways of development between MOCs and colorectal cancer and for the first time identifies a gene called HOXD9, which turns genes on and off, and provides clues about the development of MOCs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MORCELLATION


Hysterectomy device will be covered by insurer despite danger of uterine cancer's spread
The Wall Street Journal (subscription required)
Health Care Service Corp., the nation's fourth-largest health insurer, will continue to cover laparoscopic power morcellators after considering a policy that would have curbed the surgical tools used in hysterectomies, a spokeswoman said recently.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


CERVICAL CANCER


Adavaxis submits Special Protocol Assessment request to FDA for ADXS-HPV Phase 3 clinical trial in cervical cancer
MarketWatch
Advazis, Inc., announced on June 15 that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration to initiate detailed design discussions for a Phase 3 clinical study of ADXS-HPV for the treatment of high-risk, locally advanced cervical cancer (HRLACC). The Phase 3 trial is planned to be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation, Inc., and led by principal investigator Thomas Herzog, MD, at the University of Cincinnati Cancer Institute, Cincinnati, Ohio.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Benefit of fewer than 3 doses of HPV vaccine reported
Health Canal
Results of a combined analysis of data from two independent trials of the human papillomavirus vaccine strengthen previous findings from one of the trials that young women who received three, two, or one dose of the HPV 16/18 AS04-adjuvanted vaccine were equally protected against infection with the HPV types included in the vaccine four years after vaccination. The two trials whose data were pooled for this study were the National Cancer Institute-sponsored Costa Rica Vaccine Trial and the GSK Biologicals SA-sponsored Papilloma Trial against Cancer In young Adults trial.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


PALLIATIVE CARE


Earlier introduction of palliative care in advanced cancer patients associated with lower hospital costs
Journal of Clinical Oncology via The Medical News
Earlier introduction of palliative care for patients hospitalized with advanced cancer is associated with lower hospital costs, according to a new study published in the Journal of Clinical Oncology. The findings support a growing body of evidence that suggests that early provision of palliative care not only enhances the quality of medical care received by patients and families with serious illness, but does so at a lower cost than traditional oncologic care.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

June 10, 2015
June 3, 2015
May 27, 2015
May 20, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063